Mexico clears Wegovy oral tablet, a first for Latin America

Mexico's health regulator approved the Wegovy oral tablet for weight management, making the country the first in Latin America to authorize a 25 mg daily semaglutide pill ^[1]. Novo Nordisk said the Federal Commission for the Protection against Sanitary Risk, known as Cofepris, granted the clearance on Monday ^[1].

The approval is not limited to weight loss. It covers adults who have obesity, or who have overweight plus at least one weight-related condition ^[1]. The label also includes an indication to reduce major adverse cardiovascular events in people with established cardiovascular disease ^[1].

The product is prescription-only. Patients take one tablet a day on an empty stomach, the company told reporters ^[1]. Mike Vivas, medical director of Novo Nordisk Mexico, said the oral 25 mg dose offers the same reliable science as the injectable version, in a form that fits simply into a daily morning routine ^[1]. He called the decision a significant step forward in how obesity is treated and said it opens the door to comprehensive, long-term care for a condition that, by the company's count, affects three of every four Mexican adults ^[1]. That figure comes from the company rather than an independent measure cited in the coverage ^[1].

Availability questions remain

Novo Nordisk expects the tablet to reach Mexican pharmacies "during the next quarters," but has not disclosed a launch date, a price or a distribution plan ^[1].

Coverage of the decision cited the OASIS-4 trial, which showed large average weight losses among treated adults and supports the pill as a non-injectable alternative to weekly semaglutide injections ^[1]. The average weight-loss figures from that trial were not included in the coverage, so the size of the effect has not been reported ^[1].

Public health authorities and World Health Organization guidance stress that GLP-1 medicines belong within comprehensive care, pointing to unresolved questions about long-term safety, cost and equal access ^[1]. Regulators and clinicians are also watching pricing, insurance coverage and counterfeit products ^[1].

Why it matters for patients

An oral option changes how a patient takes the medicine, not what the medicine is. The tablet is semaglutide, delivered as a daily pill rather than a weekly injection ^[1]. For people who dislike needles or find injections inconvenient, that is a practical difference; it is not a different drug ^[1].

Approval does not mean the pill is on shelves. With no disclosed price, launch date or distribution plan, it is not yet known when the tablet will be sold in Mexico, what it will cost, or whether insurers or public programs will pay for it ^[1]. WHO has flagged cost and access as open problems for GLP-1 drugs generally ^[1].

Counterfeit versions are another concern regulators and clinicians are tracking as this drug class expands ^[1]. The coverage does not describe any confirmed counterfeit cases tied to this approval ^[1].

For patients in the United States, this decision changes nothing about what is available or covered at home. Its relevance is in showing how regulators outside the U.S. are handling oral GLP-1 products for weight management ^[1].

What happens next

The only timing the company has given is "during the next quarters" ^[1]. No launch date, price or distribution plan has been disclosed, so there are no dated milestones to track yet ^[1].